
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is a financially sound company with a strong track record of revenue growth and a solid pipeline for future growth. While competition and risks are present in the market, their innovative product offerings and clinical data make them a top player in the diabetes technology industry. With a strong global presence and expanding into the MDI segment, Minimed Group has the potential to continue their positive growth trajectory and retain their position as a market leader.
Bears say
Minimed Group is facing regulatory risk and pressure to provide economically attractive solutions, causing potential competition and limiting pricing power and compressing margins. The company also has limited ability to target customers, and may face reimbursement limitations in the future. Additionally, the company has dealt with FDA warning letters in the past, causing delays in product approvals and potential operational delays. There is no known cure for diabetes and competition is strong in the market, with many other companies offering similar technologies.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares